recognises that need to pay particular attention to the situation of smaller EU Member States, Cyprus, Ireland and Malta in particula;
stresses in particular the central role of a functioning, fair and efficient internal market;
welcomes the packaging requirements for UK products included in the package;
draws attention to the need for a timely and sustainable solution, which should be developed within the framework of the European Pharmaceutical Strategy.
EESC opinion: Medicinal products for human and investigational use / Derogations
